Navigation Links
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
Date:4/23/2013

Valeant expects to complete the tender offer and consummate the merger promptly after the AMC's approval of the acquisition is received.  Except for the extension of the offer expiration date, all other terms and conditions of the offer remain unchanged. Stockholders who have already tendered their shares of common stock of Obagi do not have to re-tender their shares or take any other action as a result of the extension of the expiration date of the offer.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements
This press release contains forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Obagi, satisfaction of closing conditions and the timing of closing.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect the proposed business combination of the companies and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the acquisition will not close when expected or at all; the risk that Valeant's business and/or Obagi's business will be adversely impacted during t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
2. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
5. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
6. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
7. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
8. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
9. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
10. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
11. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Global biostimulants ... 2019 growing at an estimated CAGR of 12.5%. ... healthy food products with least ecological impacts, farmers ... fertilizers to boost crop yield more effectively & ... that can improve the return on investments. , ...
(Date:11/26/2014)... 2014 2014 Deep Research Report ... research report on the Global Palmitic Acid industry. ... Acid, basic information, including definition, classification, application, industry ... analysis, etc. , For international and China ... market in China and other countries or ...
(Date:11/26/2014)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... detection of foodborne pathogens, today announced that Paul G. ... Annual Healthcare Conference on December 2, 2014 at 4:30pm ... Palace in New York, NY . ... its operations, strategies and prospects may be discussed. To listen ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 VolitionRx ... developing diagnostic tests for cancer and other conditions, today announced ... presented at the Science for Business BioWin Day 2014, being ... . The data come from VolitionRx,s lung cancer pilot study, ... of the Centre Hospitalier Universitaire (CHU) de Liege in ...
Breaking Biology Technology:2019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... DURHAM, N.C., Sept. 9 Oxygen Biotherapeutics, Inc. (OTC ... mailed today, asks shareholders to approve a 1-for-15 reverse stock split ... "At last years, general annual meeting we explained the ... and we promised to seek a listing change as soon as ...
... 9 Orexigen((R) )Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company ... speaking at two upcoming investor conferences. The details are as follows: ... Healthcare Unplugged Conference, Date: September 15, 2009, ... Hotel, New York, Speaker: Michael Narachi, President and Chief ...
... DNA Genotek,s Oragene•ANIMAL ... cause of Chiari-like Malformation and syringomyelia in dogs. Chiari-like malformation is a neurological disorder where ... crowds the spinal cord, putting pressure on both the brain and spine resulting in many ... Ottawa, ON ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split 2DNA Genotek's Oragene●ANIMAL DNA Collection Kit Plays Key Role in Determining the Genetic Cause of Chiari Malformation in Dogs 2DNA Genotek's Oragene●ANIMAL DNA Collection Kit Plays Key Role in Determining the Genetic Cause of Chiari Malformation in Dogs 3
(Date:11/4/2014)... GABLES, Fla. (November 4, 2014) — Think about the ... ask: How do neighboring cells know that they are ... and how do these tissues find the correct place ... are answering these crucial questions. , In a new ... use to communicate with their surrounding neighbors, at the ...
(Date:11/4/2014)... 4, 2014   Neurotechnology , a provider ... the latest version of its fingerprint matching algorithm ... MINEX evaluation organized by NIST. The MINEX ... the INCITS 378 fingerprint standard template format. MINEX ... tenders in the United States ...
(Date:11/3/2014)... from Australia report that low birth weight and preterm ... hip replacements in adulthood. Findings published in the American ... Research , indicate that low birth weight and pre-term ... due to OA as adults. , According to ... 25 are diagnosed with clinical OA. Symptoms of OA ...
Breaking Biology News(10 mins):The inside story: How the brain and skull stay together 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3Preterm, low birth-weight babies may need new hips in adulthood 2
... never good for you, but washing that meal down with ... of Guelph study. Researcher Marie-Soleil Beaudoin has discovered not ... eating a high-fat meal, but that the spike doubles after ... to levels similar to those of people at risk for ...
... Durham, NC ,Outer, tree canopy leaves influence the sunlight ... new study. The shape and physiology of leaves within ... on their position within the tree crown. This phenomenon is ... stress and use resources. A new study describes ...
... older doesn,t mean giving up muscle strength. Not only ... comes with age, but the Golden Years can be a time ... System. "Resistance exercise is a great way to ... function more readily in daily life," says Mark Peterson, Ph.D., a ...
Cached Biology News:Got a craving for fast food? Skip the coffee, study says 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 3Older and stronger: Progressive resistance training can build muscle, increase strength as we age 4
... Synthetic peptide derived from the C terminal ... This peptide sequence is downstream from ... polyclonal Connexin 36 antibody Cat. No. 51-6300. ... Reactivity: Mouse (positive control: mouse Connexin ...
...
...
...
Biology Products: